Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene receives $15.3 Million from the Sale of Securities Held for Sale
information fournie par Boursorama CP 17/07/2023 à 17:45

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Strasbourg, France, July 17, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese biopharmaceutical company.

Following this transaction, which completion was expected for mid-2023, Transgene reaffirms its financial visibility until early 2024.

Contacts
Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04

Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)203 928 6900
transgene@medistrava.com

Valeurs associées

TRANSGENE
0,8290 EUR Euronext Paris -0,72%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 027,61 +0,57%
Pétrole Brent
109,23 -1,52%
SOITEC
156,8 +9,54%
HAFFNER ENERGY
0,1526 +10,10%
NANOBIOTIX
35,8 -6,96%
Chargement...

Pages les plus populaires

L'offre BoursoBank